1. Home
  2. GSM vs GERN Comparison

GSM vs GERN Comparison

Compare GSM & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ferroglobe PLC

GSM

Ferroglobe PLC

HOLD

Current Price

$3.29

Market Cap

730.6M

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.27

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSM
GERN
Founded
2015
1990
Country
United Kingdom
United States
Employees
N/A
258
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
730.6M
808.3M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
GSM
GERN
Price
$3.29
$1.27
Analyst Decision
Strong Buy
Hold
Analyst Count
1
3
Target Price
$6.00
$2.17
AVG Volume (30 Days)
1.5M
14.8M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
1.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.36
$26.91
Revenue Next Year
$17.85
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.10
$1.04
52 Week High
$5.74
$2.01

Technical Indicators

Market Signals
Indicator
GSM
GERN
Relative Strength Index (RSI) 32.69 47.95
Support Level N/A $1.23
Resistance Level $4.68 $1.30
Average True Range (ATR) 0.19 0.08
MACD -0.06 0.02
Stochastic Oscillator 16.27 47.44

Price Performance

Historical Comparison
GSM
GERN

About GSM Ferroglobe PLC

Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's operating segments include Canada - Silicon Metals, Canada - Silicon Alloys, U.S. - Silicon Metals, U.S. - Silicon Alloys, Europe - Manganese Alloys, Europe - Silicon Metals, Europe - Silicon Alloys, South Africa - Silicon Metals, South Africa - Silicon Alloys, and Other segments. The primary raw materials the company uses to produce its electrometallurgy products include its coal and quartz mining operations and its silicon metal and ferroalloy production. The firm generates key revenue from Silicon metal and Manganese-based alloys.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: